Pharmaceuticals

Phase 1 data for Marea Therapeutics’ MAR002 suggests a potential new era for acromegaly treatment, promising better control with far fewer injections.

With a landmark therapy for Sanfilippo Syndrome nearing the FDA, Spruce adds veteran marketing and finance chiefs. A look at the talent behind the transition.

A new, single-shot vaccine for dogs targets two spreading diseases. This innovation aims to make vet visits less stressful and close critical health gaps.

Amid new Ebola fears, one biotech's rapid C1 platform promises 15-day biologics, eyeing a $25B market beyond just pandemic response. But can it deliver?

As 250 million people await a drug for lymphatic diseases, Celltaxis appoints a new CEO to drive its promising inflammation-targeting therapy toward the finish line.

A missed clinical trial endpoint is often the end. For Elicio Therapeutics, a deeper data dive reveals a potential path forward for a high-need patient group.

Tiziana Life Sciences’ chairman just increased his massive stake. We analyze if this is a vote of confidence in its novel MS drug or a risky bet on a fragile biotech.

New data reveals an oral drug can halt severe hereditary angioedema attacks in minutes, promising a future free from needles and fear for thousands.

For 20 years, Montreal's Segal Cancer Centre has quietly built a world-class innovation engine. We dissect its unique model where research, care, and funding converge.

A new partnership between Argonaut and Ensera aims to untangle complex supply chains for drug-device products, potentially leveling the field for smaller innovators.

A small Canadian firm's breakthrough in water technology could slash energy use in major industries. But can it overcome the hurdles to commercialization?

China's Atom Therapeutics is advancing a dual-threat pipeline, with novel drugs for gout and a groundbreaking anti-inflammatory aimed at cardiovascular disease.

While biopharma braces for Medicare price negotiations, Halozyme claims immunity. Is its tech-licensing model the new blueprint for resilience or just a loophole?

Aussie biotech ENA Respiratory secures crucial US patents for its novel immune modulator, signaling a major strategic move in the multi-billion dollar fight against COPD.

With UK approval for its EURneffy 1 mg nasal spray, ALK is set to disrupt the pediatric anaphylaxis market by offering a game-changing needle-free alternative.

Akeso's new breast cancer trial is more than a clinical step; it's a key move in a bold strategy to dominate next-gen cancer therapy and capture a lucrative market.

Stunning new US/EU data for BTK inhibitor orelabrutinib signals a major push into Western markets, challenging established blood cancer therapies.

A Dutch biotech is in late-stage trials for nizubaglustat, a drug targeting rare, fatal neurological disorders. A look at the science, strategy, and hope.

A massive 15,000-patient study on an existing therapy could upend respiratory care, combat antibiotic resistance, and deliver a bottom-line windfall.

A breakthrough publication identifies a novel protein, LanCL1, as a key target for neuropathic pain, validating a new class of drugs for millions of sufferers.